Monohydroxyethylrutoside as protector against chronic doxorubicin-induced cardiotoxicity.

S.A.B.E. van Acker, K. Kramer, J.A. Grimbergen, D.J. van den Berg, W.J.F. van der Vijgh, A. Bast

Research output: Contribution to JournalArticleAcademicpeer-review


The clinical use of the antitumour agent, doxorubicin, is largely limited by the development of a cumulative dose‐related cardiotoxicity. This toxicity is generally believed to be caused by the formation of oxygen free radicals. In earlier studies it was established that flavonoids, naturally occurring antioxidants, can provide some degree of protection. In this study we investigated whether 7‐monohydroxyethylrutoside (monoHER), a powerful antioxidative flavonoid with extremely low toxicity, can provide protection to an extent comparable to the clinically successful Cardioxane (ICRF‐187). Balb/c mice of 20–25 g were equipped i.p. with a telemeter to measure ECG. They were given 6 i.v. doses of doxorubicin (4 mg kg
Original languageEnglish
Pages (from-to)1260-1264
Number of pages4
JournalBritish Journal of Pharmacology
Publication statusPublished - 1995


Dive into the research topics of 'Monohydroxyethylrutoside as protector against chronic doxorubicin-induced cardiotoxicity.'. Together they form a unique fingerprint.

Cite this